Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566024 | 1.00 | AR (0.45) | ARUSP2MAPTMRGPRX4LMNA | |
| Hydrochloric Acid SCHEMBL29741557 | 0.99 | AR (0.44) | ARUSP2MAPTMRGPRX4LMNA | |
| SCHEMBL23235800 | 0.88 | MRGPRX4 (0.48) | ARMAPTMRGPRX4ICMTSLC6A4 | |
| Hydrochloric Acid SCHEMBL23235782 | 0.87 | MRGPRX4 (0.47) | ARMAPTMRGPRX4ICMTSLC6A4 | |
| SCHEMBL23235862 | 0.85 | AR (0.55) | ARUSP2MAPTMRGPRX4LMNA | |
| SCHEMBL23541195 | 0.84 | MRGPRX4 (0.43) | ARMRGPRX4XDH | |
| Hydrochloric Acid SCHEMBL34433935 | 0.83 | MRGPRX4 (0.42) | ARMRGPRX4XDH | |
| SCHEMBL3490042 | 0.80 | MAOB (0.57) | ARUSP2MAPTMRGPRX4LMNA | |
| SCHEMBL23235861 | 0.80 | MAOB (0.56) | AR | |
| SCHEMBL30170765 | 0.79 | AR (0.55) | ARCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4603484-A2 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-119837855-A | Compounds for the treatment of bacterial infections and for the enhancement of antibiotics | 乔治亚州大学研究基金会 | 2025-04-18 | — | — | CN | disclosed |
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4076420-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114845708-A | Compounds for treating bacterial infections and enhancing antibiotics | 乔治亚州大学研究基金会 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | BPGM, MYD88, PGLS | AR 4523/4885USP2 3429/4885MAPT 3202/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | AR 3082/4885USP2 2372/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.